TY - JOUR
T1 - Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
AU - Tempero, Margaret A.
AU - Malafa, Mokenge P.
AU - Al-Hawary, Mahmoud
AU - Behrman, Stephen W.
AU - Benson, Al B.
AU - Cardin, Dana B.
AU - Chiorean, E. Gabriela
AU - Chung, Vincent
AU - Czito, Brian
AU - Chiaro, Marco Del
AU - Dillhoff, Mary
AU - Donahue, Timothy R.
AU - Dotan, Efrat
AU - Ferrone, Cristina R.
AU - Fountzilas, Christos
AU - Hardacre, Jeffrey
AU - Hawkins, William G.
AU - Klute, Kelsey
AU - Ko, Andrew H.
AU - Kunstman, John W.
AU - LoConte, Noelle
AU - Lowy1, Andrew M.
AU - Moravek, Cassadie
AU - Nakakura, Eric K.
AU - Narang, Amol K.
AU - Obando, Jorge
AU - Polanco, Patricio M.
AU - Reddy, Sushanth
AU - Reyngold, Marsha
AU - Scaife, Courtney
AU - Shen, Jeanne
AU - Vollmer, Charles
AU - Wolff, Robert A.
AU - Wolpin, Brian M.
AU - Lynn, Beth
AU - George, Giby V.
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patientswith pancreatic cancer. Although survival rates remain relatively unchanged, newermodalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced andmetastatic disease.
AB - Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patientswith pancreatic cancer. Although survival rates remain relatively unchanged, newermodalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced andmetastatic disease.
KW - Adenocarcinoma/diagnosis
KW - Humans
KW - Pancreatic Neoplasms/diagnosis
UR - https://www.scopus.com/pages/publications/85103494776
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000655302000009&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2021.0017
DO - 10.6004/jnccn.2021.0017
M3 - Article
C2 - 33845462
SN - 1540-1405
VL - 19
SP - 439
EP - 457
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 4
ER -